ATR inhibition is lethal with numerous cancer-associated changes, including oncogenic stress (oncogenic RAS mutations, MYC and G1/S-specific cyclin-E1 (CCNE1) overexpression), deficiencies in DNA repair (TTP53, BRCA1/2, partner and localizer of BRCA2 (PALB2) and ATM loss) and other defects [110]. This evidence concerns the gene BRCA1 and cancer.